We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Scana Corp. (delisted) | NYSE:SCG | NYSE | Ordinary Share |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 47.78 | 0.00 | 01:00:00 |
RNS Number:8203I Schering AG 17 March 2003 "ABOVE" MS Study with Betaferon(R) to explore benefits of increasing dose and frequency of beta interferon Berlin, March 17, 2003 - Schering AG, Germany (FSE: SCH, NYSE: SHR) announced today that its U.S. subsidiary, Berlex Laboratories, Inc., is starting a clinical trial to evaluate the effect of an increased beta interferon dose and frequency in patients with relapsing-remitting multiple sclerosis (MS) or patients being treated with a lower-dose, once-weekly MS therapy. The study, known as "ABOVE" (Interferon beta-1a vs. Interferon beta-1b Observation of Efficacy), will compare the outcome of continuing once-weekly Avonex(R) (interferon beta-1a) versus changing to a high-dose, high-frequency regimen with Betaferon(R) (interferon beta-1b) for SC Injection. About ABOVE In this randomized, rater-blinded study, patients diagnosed with relapsing-remitting MS who currently are being treated with Avonex(R) - and have received the drug for at least the previous six months - will randomly be assigned to either continue Avonex(R) treatment or change to Betaferon(R). Patients who are treated with Betaferon(R) will increase their dose over several weeks according to the study protocol. Patients in both treatment arms will participate in the study for a total of two years. Efficacy will be measured by the number of patients who are relapse-free at the end of the treatment period, comparing those treated with Betaferon(R) and those treated with Avonex(R). This will be the largest therapeutic MS study ever conducted, involving more than 75 research centers nationwide. Patient enrollment is beginning immediately and will continue through 2004. Schering AG is a research-based pharmaceutical company. Its activities are focused on four business areas: Gynecology&Andrology, Diagnostics& Radiopharmaceuticals, Dermatology as well as Specialized Therapeutics for disabling diseases in the fields of the central nervous system, oncology and cardiovascular system. As a global player with innovative products Schering AG aims for leading positions in specialized markets worldwide. With in-house R&D and supported by an excellent global network of external partners, Schering AG is securing a promising product pipeline. Using new ideas, Schering AG aims to make a recognized contribution to medical progress and strives to improve the quality of life: making medicine work This press release has been published by Corporate Communication of Schering AG, Berlin, Germany. Your contacts at Corporate Communication: Business: Dr Friedrich von Heyl, T: +49-30-468 152 96; friedrich.vonheyl@schering.de Investor Relations: Peter Vogt, T: +49-30-468 128 38; peter.vogt@schering.de Pharma: Dr Claudia Schmitt, T: +49-30-468 158 05, claudia.schmitt@schering.de Your contacts in the US: Media Relations: Jeanine O'Kane, T:+1-973-487 2095, jeanine_O'kane@berlex.com Investor Relations: Joanne Marion, T: +1-973-487 2164, joanne_marion@berlex.com Find additional information at: www.schering.de/eng Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and Schering AG's plans and objectives to differ materially from those expressed or implied in the forward-looking statements. Certain factors that may cause such differences are discussed in our Form 20-F and Form 6-K reports filed with the U.S. Securities and Exchange Commission. Schering AG undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise. This information is provided by RNS The company news service from the London Stock Exchange END RESBXGDXSSBGGXR
1 Year Scana Chart |
1 Month Scana Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions